Literature DB >> 791430

L-dopa and (-)-deprenil in the treatment of Parkinson's disease: a long-term study [proceedings].

L Ambrozi, W Birkmayer, P Riederer, M B Youdim.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1976        PMID： 791430      PMCID： PMC1667603     

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN： 0007-1188            Impact factor:   8.739


× No keyword cloud information.
  5 in total

1.  The potentiation of the anti akinetic effect after L-dopa treatment by an inhibitor of MAO-B, Deprenil.

Authors:  W Birkmayer; P Riederer; M B Youdim; W Linauer
Journal:  J Neural Transm       Date:  1975       Impact factor: 3.575

2.  Phenylisopropylmethylpropinylamine (E-250), a new spectrum psychic energizer.

Authors:  J Knoll; Z Ecseri; K Kelemen; J Nievel; B Knoll
Journal:  Arch Int Pharmacodyn Ther       Date:  1965-05

Review 3.  [Modern treatment of parkinsonism].

Authors:  W Birkmayer; E Neumayer
Journal:  Z Neurol       Date:  1972

4.  [2-year experiences with a combination treatment of Parkinsonism with L-dopa and a decarboxylase inhibitor (Benserazid, Ro 4-4602)].

Authors:  W Birkmayer; W Linauer; M Mentasti; P Riederer
Journal:  Wien Med Wochenschr       Date:  1974-06-01

5.  A comparison of the pharmacological and biochemical properties of substrate-selective monoamine oxidase inhibitors.

Authors:  A J Christmas; C J Coulson; D R Maxwell; D Riddell
Journal:  Br J Pharmacol       Date:  1972-07       Impact factor: 8.739
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.